ShareValue scores for 2581.HK: Valuation 68, Quality 50, Growth 50, Health 65.
2581.HKHKEX
BenQ BM Holding Cayman Corp.
HK$2.90
(+0.69%)
Updated
2581.HKHKEX
BenQ BM Holding Cayman Corp.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Hong Kong-listed Healthcare stocks
Company Details
BenQ BM Holding Cayman Corp., through its subsidiaries, owns and operates hospitals in the People's Republic of China. It operates two general hospitals, namely Nanjing BenQ Hospital and Suzhou BenQ Hospital. The company provides medical services, including disease diagnosis and treatment, health management, and medical support; outpatient, inpatient, surgical, and related medical support services; ancillary medical services, such as laboratory testing, imaging, nursing, and other supporting services; emergency medical services; and thoracic surgery, nephrology, neurosurgery, obstetrics, critical care medicine, etc. It also offers management and healthcare services. In addition, the company provides services in the field of otolaryngology, head, and neck surgery; neurology; orthopedics; hemodialysis; gynecology and pediatrics; heart; urinary surgery; rehabilitation; galactophore; intestinal fistula and abdominal infection; and medical imaging. The company was incorporated in 2009 and is headquartered in Nanjing, China.
Score Analysis
AI Investment Thesis
BenQ BM Holding Cayman Corp. is fairly valued: its P/E of 11.7 is lower than 57% of Hong Kong-listed Healthcare peers, while P/B of 0.33 is lower than 92% and P/S of 0.32 lower than 86%.
Profitability is the weak pillar: a 2.44% net margin and 3.42% ROE beat the loss-making sector average but sit thin for hospital operators, with H1 2026 gross profit down 13.4%.
No material news in the last 30 days; the latest filing was the 5 October 2026 monthly return showing no share-capital change.